Clinical Trial Update: Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery [Phase 2]

View source ↗

Summary

The Phase 2 trial of oral microencapsulated diindolylmethane for stage II-III triple-negative, androgen receptor-positive breast cancer after chemotherapy and s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Androgen Receptor-positive Breast Cancer
• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Oral microencapsulated diindolylmethane (diindolylmethane)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Breast Cancer Female | Phase 2 | Status: WITHDRAWN